ClinicalTrials.gg
RecruitingNCT07367724Updated Mar 20, 2026

Ademetionine in Obstructive Hypertrophic Cardiomyopathy

A Phase 2 interventional study of Ademetionine 1,4-Butanedisulfonate and Placebo in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by China National Center for Cardiovascular Diseases. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by China National Center for Cardiovascular Diseases · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Cardiomyopathy, Hypertrophic with a site in China — 31 open to participants now, 44 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Planned enrollment
28th of 40
44 · median 83
Started
2026
with 8 others
Phase 2
4 of 72
2 open now
Primary completion
2027-12
later than 37 of 43 live
Registered
63rd of 72
by date
Lead sponsor
9 of 72
China National Center for Cardiovascular Diseases

Among the 72 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 28th largest by planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 37 of the 43 other live ones, and was the 63rd registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

31 of the 72 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for HCM.
  • Age ≥ 18 years at screening.
  • ≥ 50% at screening.
  • Echocardiography demonstrates a resting or provoked LVOTG ≥ 30 mmHg at screening.
  • Functional Class II-III at screening.
  • Able to perform CPET.
  • Patients receiving treatment with β-blockers or non-dihydropyridine calcium channel blockers should have been on a stable dose for at least 6 weeks prior to randomization and are expected to maintain the same medication during the trial. Who have previously received cardiac myosin inhibitors (e.g., Mavacamten) must discontinue the treatment for at least 8 weeks prior to randomization.
  • Willing and able to sign the form and comply with all scheduled study visits.

Exclusion criteria

Exclusion Criteria:

  • History of severe to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets.
  • History of psychiatric disorders, or current use of antidepressants such as clomipramine.
  • Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period.
  • Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period.
  • Currently pregnant or planning pregnancy.
  • Currently participation in another drug or device clinical trial.
  • History of any other disease with a of less than 1 year.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Active comparator
    Ademetionine group

    Drug: Ademetionine 1,4-Butanedisulfonate

  • Placebo comparator
    Placebo group

    Drug: Placebo

Interventions

  • DrugAdemetionine 1,4-Butanedisulfonate

    Ademetionine 1,4-Butanedisulfonate is the currently available marketed oral pharmaceutical formulation of S-adenosylmethionine. Its brand name is Ximeixin in China.

  • DrugPlacebo

    The placebo is a starch tablet identical in appearance, odor, and other physical properties.

06

What researchers measure

Primary outcomes

  1. Change in pVO₂ by CPET from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

Secondary outcomes

  1. Proportion of participants with ≥1 class improvement in NYHA Functional Class from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

  2. Change in KCCQ-CSS from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

  3. Change in provoked left ventricular outflow tract gradient from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

  4. Change in left ventricular mass index from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

  5. Change in left atrial volume index from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

  6. Change in E/e' from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

  7. Change in VE/VCO₂ slope by CPET from baseline to Week 16

    Time frame: From enrollment to the end of treatment at 16 weeks

Other outcomes

  1. Change in maximal left ventricular wall thickness from baseline to Week 16

    Exploratory endpoint

    Time frame: From enrollment to the end of treatment at 16 weeks

  2. Change in NT-proBNP from baseline to Week 16

    Exploratory endpoint

    Time frame: From enrollment to the end of treatment at 16 weeks

  3. Change in hs-cTnI from baseline to Week 16

    Exploratory endpoint

    Time frame: From enrollment to the end of treatment at 16 weeks

  4. Change in hs-cTnT from baseline to Week 16

    Exploratory endpoint

    Time frame: From enrollment to the end of treatment at 16 weeks

  5. Change in SF-36 from baseline to Week 16

    Exploratory endpoint

    Time frame: From enrollment to the end of treatment at 16 weeks

  6. Change in HCMSQ from baseline to Week 16

    Exploratory endpoint

    Time frame: From enrollment to the end of treatment at 16 weeks

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 43. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2025
First posted
Jan 26, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07367724
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Yu Zhang
Contact
dr_yuzhang@126.com
+86 19801288531

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion